August 2014 Volume 10, Issue 8

Volume 10, Issue 8 | August 2014

August 2014

In this Issue

Special Reports

Drug Discovery News Placeholder Image

Special Report on Nanotechnology: Finally beyond the hype?

A decade on, nanomedicines may finally be ready to jump to the fore

Q&A

Drug Discovery News Placeholder Image

Q&A: Strengthening hopes in cancer -- Immunology and combination therapies

A talk with Dr. Edward Bradley of MedImmune about his company’s role in the AstraZeneca family and the place MEDI4736 potentially holds within the overall pharmaceutical franchise

Editor's Focus

Drug Discovery News Placeholder Image

Editor's Focus: Topic of cancer

After several editorials that have been somewhat (or more than somewhat) critical of certain aspects of the pharma and biotech business, DDNews' chief editor shares some good news in the world of oncology therapeutics

Commentary

Drug Discovery News Placeholder Image

Commentary: Debunking the myths of treating hepatitis C

The Pharmaceutical Research and Manufacturers of America (PhRMA) tries to clear the air of what it sees as major misconceptions around hepatitis C therapeutics
Drug Discovery News Placeholder Image

Guest Commentary: New trend in regulatory affairs consulting delivers reduced costs and improved processes

Matthew Weinberg, CEO of The Weinberg Group, discusses how small- and mid-size pharma and biotech companies in particular can benefit by outsourcing their regulatory affairs work

Business & Government Policy

Drug Discovery News Placeholder Image

Shire saga comes to a close

Irish biopharmaceutical giant agrees to $54.8-billion deal
Drug Discovery News Placeholder Image

Salix Pharmaceuticals exercises an inversion

Company to combine with Cosmo Technologies to form Salix Pharmaceuticals plc
Drug Discovery News Placeholder Image

European Commission fines six companies

Servier and five generic companies hit with nearly $574 million in penalties for curbing entry of cheaper versions of antihypertensive medicine
Drug Discovery News Placeholder Image

Shimadzu and Indigo BioSystems begin their ASCENT

Companies will partner to leverage power of automated solution, unlock clinical data and accelerate LC-MS/MS workflows
Drug Discovery News Placeholder Image

M&A watch: AstraZeneca and Allergan still in play

As AbbVie seals the deal with Shire for an acquisition, Valeant still struggles with its hostile takeover of Allergan and market-watchers wait to see if Pfizer will set its sights on AstraZeneca again
Drug Discovery News Placeholder Image

Regulatory Updates

A roundup of recent news around designations, approvals and patent activities globally

Clinical Trials

Drug Discovery News Placeholder Image

Magic bullet?

Natural substance could be real cure for AIDS, says Hemispherx
Drug Discovery News Placeholder Image

Cancer progress for Merrimack

Phase 3 study of MM-398 combination therapy sees improved overall survival in pancreatic cancer
Drug Discovery News Placeholder Image

Threshold for success

Prodrug could revolutionize hypoxic tumor therapy
Drug Discovery News Placeholder Image

Building a bridge

Acquisition of NIH sickle cell drug candidate by Baxter could start to close gap between rare diseases and cures
Drug Discovery News Placeholder Image

An antidote for Factor Xa inhibitors

Portola Pharmaceuticals will partner with Daiichi Sankyo for Phase 3 studies of andexanet alfa for anticoagulant patients

Discovery

Drug Discovery News Placeholder Image

Targeting adenocarcinoma

Genomic sequencing of lung cancer reveals novel mutation and potential therapeutic pathway
Drug Discovery News Placeholder Image

Just a gut feeling

Janssen R&D, with trio of business and academic partnerships, researches microbiomes for treating IBD, gut diseases
Drug Discovery News Placeholder Image

Trio unite against epilepsy

Intellimedix, Pfizer and Epilepsy Foundation seek a drug discovery platform
Drug Discovery News Placeholder Image

Forging a ‘deal of complementarity’

Evotec and Fraunhofer collaborate in joint drug discovery programs
Drug Discovery News Placeholder Image

It’s all academic

Alzheimer’s disease DNA-sequencing project receives a $24-million boost

Preclinical

Drug Discovery News Placeholder Image

Preclinical potential

Alnylam’s investigational RNAi therapeutic demonstrates up to 98.7-percent knockdown of serum C5
Drug Discovery News Placeholder Image

Becoming a master of the domain

Domainex breathes easier after lead compound in preclinical COPD model proves potent
Drug Discovery News Placeholder Image

Cells across the sea

International Stem Cell Corp. finds potential for its stem cells in Europe, Asia
Drug Discovery News Placeholder Image

Taking funding to the web

Batu Biologics passes halfway point in crowdfunding goal
Drug Discovery News Placeholder Image

Galectin Therapeutics says GR-MD-02 is efficacious in preclinical model of fatty liver disease with fibrosis

Diabetic mice treated for the disease with GR-MD-02 showed reduction in liver weight, liver-to-body weight ratio and plasma triglyceride levels

Diagnostics

Drug Discovery News Placeholder Image

Spotting Alzheimer’s early

Proteome Sciences, King’s College London take one small step toward overcoming early-onset Alzheimer’s by 2025
Drug Discovery News Placeholder Image

Biomarker with promise

Merrimack Pharmaceuticals identifies potential biomarker and treatment for multiple cancers, prepares diagnostic assays for future studies
Drug Discovery News Placeholder Image

DNA leading the way

AutoGenomics and Genomas partner to develop DNA-guided diagnostic systems
Drug Discovery News Placeholder Image

Seeking a partner

Okayama University research opens potential for non-invasive ‘liquid biopsy’ method to capture circulating tumor cells

Research & Development

Drug Discovery News Placeholder Image

Merck and Mersana ‘flex’ their muscles

In new collaboration, the partners will work together to develop next-generation ADCs
Drug Discovery News Placeholder Image

American CryoStem signs up two

Company announces agreements with UHV Technologies for cancer research, HIT Hong Kong for cosmetic applications
Drug Discovery News Placeholder Image

A candidate for HER2

DepYmed announces validation of Trodusquemine as therapeutic candidate for HER2-positive breast cancer
Drug Discovery News Placeholder Image

BioDiscovery awarded NIH SBIR grant to improve TCGA copy number profiles

Huntsman Cancer Institute at the University of Utah selected to assist in developing and validating new product to improve the copy number variation data from The Cancer Genome Atlas
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue